A new computer tool sorts brain tumors into risk groups
Original title: MuTATE: an interpretable multi-endpoint machine learning framework for automated molecular subtyping in cancer.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was done on cells in a lab, not in people. It is a very early step.
This is a computer tool tested on stored tumor samples, not a treatment, and it is not used in clinics yet.
The short version
Researchers built a computer tool that tries to sort tumors into risk groups more accurately than the methods doctors use now.
What was studied. Researchers built a tool called MuTATE that reads the genetic details of a tumor and places it in a risk group. They tested it on 18,400 computer simulations and on 682 patient tumor samples from three cancers, including lower grade glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are graded 1 to 4 by how fast they tend to grow. See the glossary.
What they found. MuTATE was more accurate than the risk models used now, and it was easier to follow how it reached its answer. In lower grade glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are graded 1 to 4 by how fast they tend to grow. See the glossary, it moved 13% of cases that had been called low risk into higher risk groups. It also moved 19% of cases that had been called high risk into even higher risk groups.
What this means, and what it doesn't
What it could mean: If a tool like this holds up, it could help doctors get a clearer picture of how serious a tumor is. That picture is part of how treatment gets planned. It is a tool for sorting and predicting, not a treatment.
What it doesn't mean: This does not mean a new treatment, and it is not a cure. The tool was tested on stored tumor samples and computer simulations, not on people getting care in a clinic. No one was treated with it, and no one lived longer because of it. It has not been approved or put into regular practice. It would need much more testing before a doctor could use it for you.
Source: PubMed, July 3, 2025 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.